Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Summary Targeted protein degradation (TPD) is a promising strategy to remove deleterious proteins for therapeutic benefit and to probe biological pathways. The past two decades have witnessed a surge in the development of technologies that rely on intracellular machinery to degrade challenging cytosolic targets. However, these TPD platforms leave the majority of extracellular and membrane proteins untouched. To enable degradation of these classes of proteins, internalizing receptors can be co-opted to traffic extracellular proteins to the lysosome. Sweeping antibodies and Seldegs use Fc receptors in conjunction with engineered antibodies to degrade soluble proteins. Recently, lysosome targeting chimeras (LYTACs) have emerged as a strategy to degrade both secreted and membrane-anchored targets. Together with other newcomer technologies including antibody-based PROTACs (AbTACs), modalities that degrade extracellular proteins have promising translational potential. This perspective will give an overview of TPD platforms that degrade proteins via outside-in approaches and focus on the recent development of LYTACs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 1×
“Advances in event-driven strategies fueled the development of proteolysis targeting chimeras (PROTACs) (Sakamoto et al., 2001; Winter et al., 2015), immunomodulatory drugs (IMiDs) (Krönke et al.”
BackgroundEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“As a result, strategies that inhibit PCSK9 from interacting with LDLR and enable LDLR to lower plasma LDL cholesterol have become approved therapeutics (Robinson et al., 2015; Sheridan, 2015; Sabatine et al., 2015).”
BackgroundLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · cited 1×
“, 2015), immunomodulatory drugs (IMiDs) (Krönke et al., 2014; Lu et al., 2014), Trim-Away (Clift et al.”
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · cited 2×
“Advances in event-driven strategies fueled the development of proteolysis targeting chimeras (PROTACs) (Sakamoto et al., 2001; Winter et al., 2015), immunomodulatory drugs (IMiDs) (Krönke et al.”
BackgroundThe Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199 · cited 3×
“Nevertheless, we evaluated the pharmacokinetics of M6Pn-LYTACs in vivo, and observed that Ctx-M6Pn is sustained in plasma for greater than 72 hours (Banik et al., 2020).”
BackgroundMethodSelf-citationThe dTAG system for immediate and target-specific protein degradation
Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118 · cited 1×
“…chimeras (PROTACs) (Sakamoto et al., 2001; Winter et al., 2015), immunomodulatory drugs (IMiDs) (Krönke et al., 2014; Lu et al., 2014), Trim-Away (Clift et al., 2017), SNIPERs (Naito et al., 2019), dTAGs (Nabet et al., 2018, 2020), AUTACs (Takahashi et al., 2019), and ATTECs (Li et al., 2019).”
GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics
Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681 · cited 1×
“For example, proprotein convertase subtilisin kexin 9 (PCSK9) binds to the low-density lipoprotein receptor (LDLR) preventing LDLR recycling to the cell surface and promoting trafficking to the lysosome for degradation (Benjannet et al., 2004; Maxwell et al., 2005; Lagace et al., 2006).”
BackgroundAUTACs: Cargo-Specific Degraders Using Selective Autophagy
Takahashi, D., Moriyama, J., Nakamura, T., Miki, E., Takahashi, E., Sato, A., Akaike, T., Itto-Nakama, K., & Arimoto, H. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.009 · Cited by 675
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551 · cited 2×
“Unlike traditional PROTACs, it is unclear if AbTACs work catalytically, as the PD-L1 levels recovered after a wash-off (Cotton et al., 2021).”
BackgroundAllele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds
Li, Z., Wang, C., Wang, Z., Zhu, C., Li, J., Sha, T., Ma, L., Gao, C., Yang, Y., Sun, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1722-1 · Cited by 551
A Method for the Acute and Rapid Degradation of Endogenous Proteins
Clift, D., McEwan, W. A., Labzin, L. I., Konieczny, V., Mogessie, B., James, L. C., & Schuh, M. (2017) · Cell · doi:10.1016/j.cell.2017.10.033 · Cited by 531 · cited 2×
“, 2014), Trim-Away (Clift et al., 2017), SNIPERs (Naito et al.”
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., Xie, L., Huang, Q., Li, F., & Li, C.-Y. (2020) · Nature · doi:10.1038/s41586-020-2911-7 · Cited by 490 · cited 1×
“More recently, it was revealed that PCSK9 also traffics major histocompatibility protein class I (MHC I) from the tumor cell surface to the lysosome for degradation, and that inhibition of PCSK9 can induce intratumoral infiltration by T cells and improve the response to immune check point therapy (Liu et al., 2020).”
BackgroundMaxwell, K. N., Fisher, E. A., & Breslow, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409736102 · Cited by 415
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · cited 2×
“Seldegs—Ward and colleagues first developed “FcRn blockers” or Abdegs to target circulating IgG by engineering the Fc region to enhance FcRn binding in the pH range of 6.0–7.4 (Vaccaro et al., 2005) as a method of reducing IgG levels in antibody-mediated diseases.”
MethodInfluentialRapid and direct control of target protein levels with VHL-recruiting dTAG molecules
Nabet, B., Ferguson, F. M., Seong, B. K. A., Kuljanin, M., Leggett, A. L., Mohardt, M. L., Robichaud, A., Conway, A. S., Buckley, D. L., Mancias, J. D., et al. (2020) · doi:10.1101/2020.03.13.980946 · Cited by 312
Waste disposal—An attractive strategy for cancer therapy
Salami, J., & Crews, C. M. (2017) · Science · doi:10.1126/science.aam7340 · Cited by 279
Bifunctional small molecules that mediate the degradation of extracellular proteins
Caianiello, D. F., Zhang, M., Ray, J. D., Howell, R. A., Swartzel, J. C., Branham, E. M. J., Chirkin, E., Sabbasani, V. R., Gong, A. Z., McDonald, D. M., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00851-1 · Cited by 244 · cited 1×
“MoDE-As mediated lysosomal degradation of dinitrophenol (DNP)-antibodies and cytokine macrophage migratory inhibition factor (MIF) in HEPG2 cells (Caianiello et al., 2020).”
BackgroundFirst targeted protein degrader hits the clinic
Mullard, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00043-6 · Cited by 146 · cited 1×
“IMiDs are already clinically approved drugs, and PROTACs are currently undergoing clinical trials (Mullard, 2019).”
BackgroundBensimon, A., Pizzagalli, M. D., Kartnig, F., Dvorak, V., Essletzbichler, P., Winter, G. E., & Superti-Furga, G. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.04.003 · Cited by 102 · cited 1×
“, 2018) and solute carrier transporters (Bensimon et al., 2020) using repurposed inhibitors as target binding warheads.”
BackgroundAnalyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery
Gan, Z., Ram, S., Vaccaro, C., Ober, R. J., & Ward, E. S. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00887.x · Cited by 76
Cited by
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Molecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Schreiber, S. L. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.05.004 · Cited by 112
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Metadata
- Authors
- Ahn, G., Banik, S. M., & Bertozzi, C. R.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 28
- Issue
- 7
- Pages
- 1072-1080
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W3137806971
- Cited by
- 93
- References
- 25
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.